Trajan Unlocks Portable Potential of Dried Blood Spot Sampling with hemaPEN™

Trajan Unlocks Portable Potential of Dried Blood Spot Sampling with hemaPEN™

September 01, 2015

hemaPEN™

In a world where health care costs are escalating and demands on health care systems are becoming overwhelming, Trajan Scientific and Medical (Trajan) today announces the innovation of hemaPEN™, a prototype blood collection and storage device.

Harnessing the benefits of Dried Blood Spot (DBS) sampling in an intuitive and safe portable format, hemaPEN has the potential to change the way individuals have their blood tested - eliminating the need to visit a clinic and offering precision blood sampling with the click of a button via its familiar pen design, which can be easily used by anyone including the young, elderly and people with disabilities.

The hemaPEN is the only device of its kind in the world that allows people to collect an uncontaminated and precise volume of their own blood from the fingertip at home, eliminating the need to travel to a medical clinic – not only saving time, but the superior ready-to-use DBS sample enables the laboratory to deliver more definitive test results.

After a simple finger prick, hemaPEN can be used to collect an accurate microsample of blood, placed in the mail and analysed by a laboratory – avoiding the often overwhelming load on clinics to take blood samples and alleviating stress for the patient.

hemaPEN is the first product concept from ASTech, the ARC Training Centre for Portable Analytical Separation Technologies – a $5.2 M program part funded by the Australian Research Council (ARC), University of Tasmania (UTAS) and Trajan – and has huge potential to benefit to a range of disease screening including diabetes, therapeutic drug monitoring and medical research.

hemaPEN is the result of research and investigation by ASTech Post-doctoral Research Fellow from UTAS, Dr Florian Lapierre, who holds a PhD in Micro and Nanotechnology in the field of sophisticated microfluidic device design, a Master of Science and Technology in microfluidic systems and a Master of Engineering in scientific measurement and applied business.

Dr Lapierre shared his inspiration, “Whilst researching, I was clicking my pen and thought, why have a retractable pen? So you can click when you need it, and not get ink everywhere when you don’t. hemaPEN takes the same form, collecting the blood when you want to and safely storing it inside.

“Working at ASTech gives me greater insight into developing my thinking beyond a traditional academic setting. I am undertaking my industry placement at Trajan and have a senior mentor who encourages me to think about commercialization, which has changed the way I approach my research – I’m now developing hemaPEN to fill a clear need in this particular market,” said Dr Lapierre.

Chief Executive Officer of Trajan, Stephen Tomisich says Trajan is driven by a passion to develop technologies that will impact human wellbeing.

“Whilst this first iteration of hemaPEN provides a DBS format ready for Liquid Chromatography-Mass Spectrometry (LC-MS) analysis, we are now working on future versions with various interfaces, potentially with in-built sensing technology. Excitingly, we will soon commence trialling the device with patients to determine the impact of self-sampling to their lifestyles and wellbeing,” Mr Tomisich said.

hemaPEN is an entry in the Premier’s Design Awards, which recognize and reward Victorian designers and businesses using exemplar design effectively and sustainably.

Dr Florian Lapierre, ASTech Post-doctoral Research Fellow from UTAS, currently undertaking his industry placement at Trajan Scientific and Medical - developing the hemaPEN to change the way individuals have their blood tested.
Photo: Dr Florian Lapierre, ASTech Post-doctoral Research Fellow from UTAS, currently undertaking his industry placement at Trajan Scientific and Medical - developing the hemaPEN to change the way individuals have their blood tested.

More Information
hemaPEN

Related News
Your Smartphone Transformed into a Mobile Lab
Trajan and University of Tasmania Secure Top Postdoctoral Fellows for ASTech

Download
Press Release [PDF]

Media Contact Information
Trajan Scientific and Medical
media@trajanscimed.com
+61 (0) 3 9837 4200

PR Consultancy: LBPR
lisa@lbpr.com.au
+61 (0) 429 976 718




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More